Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Costotransverse foramen block, Thoracic paravertebral plane block.
- Who it may be relevant to
- Registry conditions: Costotransverse Foramen Block, Thoracic Paravertebral Block, Thoracotomy, Lung Cancer. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer: A Randomized Controlled Trial
Overview
This study aims to compare the costotransverse foramen block (CTFB) with thoracic paravertebral block (TPVB) in patients undergoing thoracotomy for lung cancer.
Detailed description
Thoracotomy is known to be one of the most painful surgeries. Managing post-thoracotomy pain is a major clinical challenge, as about 75% of patients report moderate to severe pain afterward.
Various regional and central analgesia techniques, such as thoracic epidural analgesia (TEA), thoracic paravertebral block (TPVB), and erector spinae plane block (ESPB), are employed in a multimodal approach. Although TEA has traditionally been considered the gold standard for thoracotomy pain control, concerns about its side effects have prompted the exploration of alternatives.
The costotransverse foramen block (CTFB), a recently introduced technique, has been examined in both cadaveric and case studies.
Interventions
- Other Costotransverse foramen block
Patients will receive an ipsilateral ultrasound-guided costotransverse foramen block with injection of 20 ml bupivacaine 0.25%. - Other Thoracic paravertebral plane block
Patients will receive an ipsilateral ultrasound-guided thoracic paravertebral plane block with injection of 20 ml bupivacaine 0.25%.
Primary outcome measures
- Total morphine consumption [Time frame: 24 hours postoperatively]
Secondary outcome measures (7)
- Duration of analgesia [Time frame: 24 hours postoperatively]
- Degree of pain [Time frame: 48 hours postoperatively]
- Intraoperative fentanyl consumption [Time frame: Intraoperatively]
- Mean arterial blood pressure [Time frame: 4 hours postoperatively]
- Heart rate [Time frame: 4 hours postoperatively]
- Incidence of block-related side effects [Time frame: 4 hours postoperatively]
- Incidence of side effects [Time frame: 4 hours postoperatively]
Eligibility criteria
Inclusion criteria
- Age > 18 years and ≤ 65 years old.
- American Society of Anesthesiologists (ASA) physical status II-III.
- Body mass index 18-35 kg/m2.
- Patients scheduled for thoracotomies for lung cancer.
Exclusion criteria
- Patient refusal.
- History of sensitivity to local anesthetics.
- History of psychological disorders.
- Contraindication to regional anesthesia, e.g., local sepsis, pre-existing peripheral neuropathies, and coagulopathy.
- Severe respiratory, cardiac, hepatic, or renal disease.
- Morbid obesity.
- Uncooperative patients.
- Patients on chronic pain therapy.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Cairo University — Cairo
Identifiers
NCT: NCT07367581 · AP2512-501-141-205